The FNDC3B, VSTM1, PLA2G4A, GOLGA3, CALR and risk score may serve as key prognostic biomarkers for the stratification and ultimately guide rational treatment of AML patients. The gene discussed is PLA2G4A; the disease is acute myeloid leukemia.